Next Article in Journal
A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia
Next Article in Special Issue
Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease
Previous Article in Journal
New Insights into the Pathophysiology and Treatment of Fibromyalgia
Previous Article in Special Issue
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessFeature PaperReview
Biomedicines 2017, 5(2), 23; doi:10.3390/biomedicines5020023

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease

Division of Hematology and Bone Marrow Transplantation, University of Kentucky, Markey Cancer Center 800 Rose Street, Lexington, KY 40536, USA
Author to whom correspondence should be addressed.
Academic Editors: Antonio Di Stasi and Ayman Saad
Received: 3 March 2017 / Revised: 16 April 2017 / Accepted: 15 May 2017 / Published: 16 May 2017
(This article belongs to the Special Issue Cell Therapy for the Treatment of GVHD)
View Full-Text   |   Download PDF [195 KB, uploaded 16 May 2017]


Regulatory T (Tregs) cells play a crucial role in immunoregulation and promotion of immunological tolerance. Adoptive transfer of these cells has therefore been of interest in the field of bone marrow and solid organ transplantation, autoimmune diseases and allergy medicine. In bone marrow transplantation, Tregs play a pivotal role in the prevention of graft-verus-host disease (GvHD). This has generated interest in using adoptive Treg cellular therapy in the prevention and treatment of GvHD. There have been several barriers to the feasibility of Treg cellular therapy in the setting of hematopoietic stem cell transplantation (HSCT) which include low Treg concentration in peripheral blood, requiring expansion of the Treg population; instability of the expanded product with loss of FoxP3 expression; and issues related to the purity of the expanded product. Despite these challenges, investigators have been able to successfully expand these cells both in vivo and in vitro and have demonstrated that they can be safely infused in humans for the prevention and treatment of GvHD with no increase in relapse risk or infections risk. View Full-Text
Keywords: Tregs; graft versus host disease (GvHD); adoptive cellular therapy; CD4+CD25+FoxP3+ T cells Tregs; graft versus host disease (GvHD); adoptive cellular therapy; CD4+CD25+FoxP3+ T cells
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Ramlal, R.; Hildebrandt, G.C. Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease. Biomedicines 2017, 5, 23.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top